Skip to content
Medical Health Aged Care

GPs commend Victorian Government for taking action on RSV

Royal Australian College of GPs 2 mins read

The Royal Australian College of GPs (RACGP) has applauded the Victorian Government’s announcement of funding for a free long-acting monoclonal antibody against respiratory syncytial virus (RSV) for unprotected newborns and eligible infants.   

Victorian Minister for Health Mary-Anne Thomas announced $18.7 million for infant immunisation will complement an expected Commonwealth-funded maternal vaccine as part of a coordinated national program.

The monoclonal antibody will be available for Victorian babies and infants whose mother was unable to be immunised or was immunised less than two weeks before delivery. The infant immunisation provides protection against the virus for about five months, covering the winter peak of RSV infections from April to September.

The RACGP has previously called on Victoria to fund immunisation against RSV for babies to reduce hospitalisations.

RACGP Victoria Deputy Char Dr Aadhil Aziz said praised the Victorian Government for taking action.

“This is a fantastic initiative from the Victorian Government, and one GPs have been calling for,” he said.

“Going back into hospital with a sick baby is a big fear for new parents. Immunisation is the best way to prevent infants from being hospitalised due to RSV, and to prevent parents having to go through that.

“We’re glad the Victorian Government has listened to patients and GPs and taken action.

“RSV among young children is far more serious than many people expect. RSV infections cause over 6000 hospitalisations each year in Australia. Around half of RSV notifications are of children under five, and infants under six months are at greatest risk.

“It’s likely the number one cause of hospitalisation among young children, and up to a quarter of them need intensive care treatment. That’s an absolute nightmare for a young family to go through.

“The safety data for monoclonal antibodies for newborns has been very reassuring. Most infants tolerate immunisation very well, and where they have a reaction, it’s usually mild and short.

“There are many things new parents have to do, and free immunisation against RSV means one less thing to worry about.”

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992media@racgp.org.au

Follow us on Twitter: @RACGP and Facebook.

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.